Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Palatin Technologies Inc PTN

Healthcare Biotechnology
Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor system. The Company’s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its new product development activities focus primarily on MC1r agonists, with the potential to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. It is also developing peptides that are active at more than one melanocortin receptor, and MC4r peptide and small molecule agonists with potential utility in obesity and metabolic-related disorders, including rare disease and orphan indications. Its product candidates include PL9643 for dry eye disease and PL8177 for the treatment of ulcerative colitis.


NYSEAM:PTN - Post by User

Palatin Technologies Inc
<< Previous
 Bullboard Posts
User Avatar Image
(241)
•••
Post by whytestockson Nov 14, 2024 8:02pm
36 Views
Post# 36314000

Palatin Reports First Quarter Fiscal Year 2025 Operating/Fin

Palatin Reports First Quarter Fiscal Year 2025 Operating/Fin
News; $PTN Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial ResultsPalatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results PR Newswire Obesity programs: Core focus on obesity includes exploratory co-administration BMT-801 study and two novel development drug candidates Phase 2 BMT-801 clinical study with M...PTN - Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities